The liver X receptors.
The liver X receptors (LXRs), members of the nuclear receptor superfamily, are potential targets for a variety of diseases. While there are many opportunities for the development of LXR-based therapeutics, there are some major hurdles, such as the ability of LXRs to cause hypertriglyceridemia, as well as some species-dependent aspects of LXR-mediated gene regulation. In addition to classical pharmacological approaches using relevant cellular and animal models, systematic molecular-based strategies will be important in overcoming these obstacles.
Lala
Deepak S
DS
Pfizer Global Research and Development, Ann Arbor, MI 48105, USA. deepak.s.lala@pfizer.com
D000544:Alzheimer Disease / Q000188:drug therapy; D000818:Animals; D050197:Atherosclerosis / Q000517:prevention & control; D001692:Biological Transport; D002784:Cholesterol / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000819:agonists / Q000502:physiology*; D003920:Diabetes Mellitus / Q000188:drug therapy; D006801:Humans; D007113:Immunity, Innate; D007249:Inflammation / Q000517:prevention & control; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists / Q000502:physiology*; D012871:Skin Diseases / Q000188:drug therapy; D014280:Triglycerides / Q000097:blood
D004268:DNA-Binding Proteins; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D018160:Receptors, Cytoplasmic and Nuclear; D014280:Triglycerides; D002784:Cholesterol